Healthcare online Keeping you up-to-date
VOL.  10     ISSUE:  2    February 2012 Medical Services Department

SQUARE Pharmaceuticals Ltd.





P G Dip. Business Management

A. S. M. Shawkat Ali

MBBS, M. Phil





Dear Doctor:

Welcome to 'e-SQUARE' . Hope you are enjoying this online healthcare bulletin.

Our current issue focused on some interesting features like

"Staph Screening !", "Colon Polyps In Women !", "Dementia !", "Endogenous Cushing's Syndrome !", "Hepatitis C Alert !", "Drug Delivery Future !".

In our regular feature, we have some new products information of SQUARE Pharmaceuticals Ltd. as well.

We will appreciate your feedback !

Click on to reply mode.

Yours sincerely,


Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE PHARMACEUTICALS LTD.

 Staph Screening !

 Some Kids' Surgery Should Include Staph Screening: Study

Screening and treatment for antibiotic-resistant bacteria benefits children undergoing open-airway surgery, according to a new study. After open-airway surgery, infection with methicillin-resistant Staphylococcus aureus can be a ‘devastating complication,’ so the development and use of an MRSA-screening and treatment regimen is essential, according to background information in the study. The researchers analyzed 197 open-airway operations conducted on children from January 2007 to March 2009. The overall prevalence of MRSA in the patients was 32.5 percent, but there were no MRSA-associated postoperative infections in patients who received antibiotics before, during and after surgery. That finding is consistent with previous studies. In view of the study result, investigators advise instituting MRSA screening and treatment protocols in patients undergoing airway surgery.

SOURCE: HealthDay News, February 2012.

Return to top

 Colon Polyps In Women !

Eating Fish May Help Ward Off Colon Polyps In Women

Eating at least three servings of fish a week may reduce women's risk of developing some types of colon polyps, according to a new study. Colon polyps are small growths on the intestinal lining that may develop into cancer. Previous research has suggested a link between inflammation and formation of colon polyps. Omega-3 fats in fish may reduce inflammation and help protect against the development of colon polyps, according to the researchers. Their study of more than 5,300 people found that women who ate at least three servings of fish a week were 33 percent less likely to develop colon polyps and also had lower levels of an inflammation-related hormone called prostaglandin E2. Prostaglandin E2 is known to be associated with adenomas or polyps in colorectal cancers and fish oil also appears to have the same beneficial effect as aspirin in reducing inflammation, said the author. Researchers were surprised to find that eating fish reduced the risk of colon polyps in women, but not in men. The difference between men and women may be linked to their background diet. Even though men are eating more omega-3 fatty acids they may also be eating more omega-6 fatty acids and that may be blunting the effect. Omega-6 fatty acids are found in meats, grains and seed oils, including corn oil. Types of fish with high levels of the protective omega-3 fatty acids include tuna, salmon and sardines. While the study found an association between fish and a lowered chance of having polyps, it did not prove that a diet rich in fish is responsible for the reduction. Other factors could play a role.

SOURCE: HealthDay News, February 2012.

Return to top

 Dementia !

Exercise a Defense Against Dementia: Study

Physical activity may reduce the risk of dementia-related death, according to a new study. Researchers assessed the health of more than 45,000 men and nearly 15,000 women, ages 20 to 88 years, in the United States and grouped them into one of three fitness categories low, middle and high. After an average follow-up of 17 years, about 4,050 participants died. Of those deaths, 164 were attributed to dementia (72 vascular dementia and 92 Alzheimer's disease). Of those 164 deaths, 123 of the people were in the low-fitness group, 23 were in the middle-fitness group and 18 were in the high-fitness group. Researchers found that people in the high- and medium-fitness groups had less than half the risk of dying as those in the low-fitness group. These findings support physical-activity promotion campaigns by organizations such as the Alzheimer's Association and should encourage individuals to be physically active. Following the current physical-activity recommendations from the American College of Sports Medicine will keep most individuals out of the low-fit category and may reduce their risk of dying with dementia, the investigator added. The study doesn't prove that exercise will prevent dementia. However, other factors may also come into play.

SOURCE: HealthDay News, February 2012.

Return to top

 Endogenous Cushing’s Syndrome !

FDA Approves ‘Mifepristone’ in Endogenous Cushing’s Syndrome

A new drug ‘Mifepristone’ is approved by the U.S. FDA to control high blood sugar levels in adults with endogenous Cushing’s syndrome. This drug is approved for use in patients with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Prior to FDA’s approval of ‘Mifepristone’, there were no approved medicine for the treatment of endogenous Cushing’s syndrome. It is a serious, debilitating and rare multisystem disorder, caused by the overproduction of cortisol (a steroid hormone that increases blood sugar levels) by the adrenal glands. This syndrome most commonly affects adults between the ages of 25 and 40. ‘Mifepristone’ blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as hyperglycemia. The safety and efficacy of ‘Mifepristone’ in patients with endogenous Cushing’s syndrome was evaluated in a clinical trial with 50 patients. A separate open-label extension of this trial is ongoing. Additional evidence supporting the agency’s approval included several safety pharmacology studies, drug interaction studies and published scientific literature. Patients experienced significant improvement in blood sugar control during ‘Mifepristone’ treatment, including some patients who had marked reductions in their insulin requirements. Improvements in clinical signs and symptoms were reported by some patients. The most common side effects experienced by patients treated with ‘Mifepristone’ in clinical trials were nausea, fatigue, headache, arthralgia, vomiting, swelling of the extremities, dizziness and decreased appetite. Other side effects of ‘Mifepristone’ include adrenal insufficiency, low potassium levels, vaginal bleeding and a potential for heart conduction abnormalities. ‘Mifepristone’ should never be used by pregnant women. Although pregnancy is an extremely rare occurrence in Cushing’s syndrome patients because of the suppressive effect of excess cortisol on female reproductive function. 

SOURCE: FDA News, February, 2012.

Return to top

 Hepatitis C Alert !

Hepatitis C Now Kills More Americans Than HIV

Deaths from hepatitis C have increased steadily in the United States in recent years, because many people don't know they have disease, a new government report says. More Americans now die of hepatitis C than from HIV, according to death records (22 million) from 1999-2007. Data reviewed by the U.S. Centers for Disease Control and Prevention (CDC). The investigators found deaths from hepatitis C surpassed deaths from HIV (15,000 from hepatitis C versus 13,000 from HIV). 73 percent of hepatitis C deaths were reported among those 45 to 64 years old. They also found that deaths from hepatitis C and B are mostly among the middle-aged. These data underscore the urgent need to address the health threat posed by chronic hepatitis B and C in the United States, said investigator. About 3.2 million Americans are infected with hepatitis C, a major cause of liver cancer and cirrhosis, the CDC authors said. An estimated one-half to three-quarters of infected adults are unaware they have the disease, which progresses slowly. Hepatitis C is spread through injection drug use, from blood transfusions received before routine blood-screening and through sexual contact. In some cases, it passes from mothers to infants. Chronic hepatitis is a leading and preventable cause of premature death in the United States. Over time, leaving viral hepatitis untreated can lead to costly care and treatment. However, early detection and intervention can be cost-effective and save lives, investigator said. Vaccines exist for hepatitis B, but not for hepatitis C. If current trends continue by 2030 deaths from hepatitis C are expected to reach 35,000 a year. The new study highlights the need to increase hepatitis awareness and the critical importance of testing. Screening will increase diagnoses and treatment, thereby reducing hepatitis-related deaths.

SOURCE: HealthDay News, February 2012.

Return to top

 Drug Delivery Future !

Implanted Microchip Might Be Future Of Drug Delivery

Remote controls may not be for just appliances anymore. In a new small study, women with severe osteoporosis were implanted with a microchip that releases bone-building drugs at the push of a button, a delivery method that could someday become common for various health conditions. Roughly 1.5-by-2.5 inches in size, the microchip significantly improved patient compliance with a drug regimen that normally requires painful daily self-injections, study authors said. The clinical trial, conducted on seven osteoporosis patients in Denmark, was the first to test a wirelessly controlled microchip in this capacity. It frees patients from the burden of managing their disease on a daily basis. There will be a class of drugs [for other conditions] that will be very suitable to use the chip. The investigators implanted the microchip just under the skin near the waistline of the seven women, who ranged from ages 65 to 70 and had been using pre-filled injection pens containing teriparatide for their severe osteoporosis. The microchip delivered the drug as effectively as daily injections, the study said. Blood tests done after the 12-month study period indicated rates of bone formation similar to when the women self-injected the drug. Because daily injections can be psychologically and physically challenging, only 25 percent of patients on teriparatide actually finish a typical 24-month regimen. But with the implanted microchip that delivered 20 timed doses controlled by doctors the compliance rate rose to 100 percent. The microchip can be implanted under local anesthesia in a doctor's office. The reservoirs pop open on a pre-programmed schedule or via a wireless signal, which can be sent from a doctor's computer or smartphone.  Researchers had modified the drug to make this possible, an effort made easier because each dose was also sealed in tiny air- and moisture-proof compartments in the microchip. Investigators hope it will approve by the U.S. FDA and will be available in the market in near future.

SOURCE: HealthDay News, February 2012.

Return to top


New Products of SQUARE Pharmaceuticals Ltd.

  Product Mevin®
  Generic Name Mebeverine
  Strength 135 mg
  Dosage form Tablet
  Therapeutic Category Antispasmodics
  Product Rosuva®  
Generic Name



5 mg

Dosage form Tablet
Therapeutic Category Statins
  Product Ciprocin IV Infusion®
  Generic Name Ciprofloxacin
  Strength 2 mg/ml
  Dosage form IV Infusion
  Therapeutic Category Quinolone Antibiotics

Return to top


Copyright © 2012 SQUARE Pharmaceuticals Ltd. All rights reserved.